WSJ Pro Venture Capital included Fesarius Therapeutics' $20 million Series A, led by Jefferson Life Sciences with Johnson & Johnson Innovation – JJDC and Empire State Development's New York Ventures, in its venture funding roundup.
WSJ Pro Venture Capital: FesariusTherapeutics Secures $20 Million in Series A Funding
